Is remote work here to stay for biopharma? Early indications point to yes
Covid-19 cases in the US have begun to ebb, following a nationwide vaccination campaign that has nearly 60% of American adults receiving at least one vaccine dose as of Tuesday. And with more and more individuals being inoculated, the biopharma industry is openly wondering how to bring its employees back to the office.
The early consensus among bigger companies indicates that some sort of new normal will take shape once the pandemic officially ends, with employees spending time both at their offices and working remotely. How quickly that develops remains an open question, however.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
